Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Surged 41.9% over 21 sessions and 17.7% on September 17. The Bunsen AI co-scientist launch, Bristol Myers Squibb deployment agreement, Tectora Therapeutics formation and upcoming clinical-data opportunities provide fresh catalysts alongside exceptional momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong net cash • Persistent losses • High R&D spend SDGR has strong liquidity and modest debt, but persistent operating losses, negative cash flow, and elevated sales/book multiples make profitability execution the key investment risk.
Price Behavior
Key Price Behavior Insights: • Modest monthly gain • Momentum weakening • Key support test Support Level: $18.77–$18.80 Resistance Level: $20.03–$20.09 SDGR is up 3% over the last month but short-term momentum is weakening below its $19.41 average; watch $18.77–$18.80 support and a break above $20.03–$20.09 for renewed upside.
Sentiment & News
Key News Insights: • BlackRock investment • Tectora launch • AI drug discovery Schrödinger faces share-price volatility but gains institutional backing and strategic momentum through Tectora Therapeutics and AI drug-discovery visibility.
AI Summary
SDGR is an enterprise pharmaceutical-AI commercialization bet—not yet a profitable software story—where Bunsen's conversion from BMS validation and rising ACV into recurring revenue is the critical upside catalyst, while sustained R&D-driven losses and cash burn make expense discipline essential before a rerating is justified.
Description
Schrödinger, Inc. develops physics-based computational tools used to identify and design novel molecules for therapeutic and materials applications, and sells that software to customers in life sciences and industrial research. The company also operates a drug discovery unit that advances preclinical and clinical programs both internally and through collaborations, serving biopharmaceutical firms, industrial companies, academic institutions and government labs worldwide; it was incorporated in 1990 and is based in New York City.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 17 | Sep 24 | SDGR | Schrödinger, Inc. | Surged 41.9% over 21 sessions and 17.7% on September 17. The Bunsen AI co-scientist launch, Bristol Myers Squibb deployment agreement, Tectora Therapeutics formation and upcoming clinical-data opportunities provide fresh catalysts alongside exceptional momentum. | Active | +0.0% |